Law360, New York (June 27, 2006, 12:00 AM EDT) -- The U.S. Court of Appeals for the Federal Circuit last week gave Israel drug maker Teva Pharmaceutical Industries Ltd. its blessing to sell a generic equivalent of Abbott Laboratories’ extended-release antibiotic Biaxin. But Teva agreed in another courtroom this week to stop selling the drug.
At root is a disagreement between lawyers for Teva and Abbott as to when the preliminary injunction barring Teva from selling the drug becomes null and void.
The injunction was granted in June 2005 by a judge in the U.S. District...
Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.